Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Phase 1
Completed
- Conditions
- Ovarian CancerEndometrial CancerSoft Tissue SarcomaTriple Negative Breast CancerPancreas CancerSolid TumorsColorectal CancerNeoplasmsBreast CancerColon Cancer
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Esperas Pharma Inc.
- Target Recruit Count
- 229
- Registration Number
- NCT02632448
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
News
No news found